trending Market Intelligence /marketintelligence/en/news-insights/trending/SanR_p-bYCoxC0CNdJVsmA2 content esgSubNav
In This List

FIT Biotech, InnaVirVax collaborate on HIV treatment

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


FIT Biotech, InnaVirVax collaborate on HIV treatment

FIT Biotech Oy is collaborating with InnaVirVax to develop an HIV treatment.

The companies will combine their proprietary immunotherapeutic HIV-vaccines to produce a drug candidate that will undergo phase 2 trial in 2017.

InnaVirVax will conduct and fund the clinical study in return for co-ownership of the immunotherapy. The companies will then seek additional third-party support and resources to further develop and commercialize the combination of the two products.